Pay in 4 interest-free payments of $5.79 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
6 Approved to reduce the risk of major adverse cardiovascular events (cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease
Human research is limited, though animal data is robust and consistent across multiple models
These findings challenge whether endogenous PNS or CNS GLP-1R signaling is essential for maintaining normal energy homeostasis
Making the Right Choice for Your Situation Choosing between Retatrutide vs Tirzepatide depends on several personal factors and your current situation
Retatrutide is a first-in-class triple hormone receptor agonist whose Phase 3 data, released through late 2025 and 2026, has pushed Canadian research interest to record highs
